[
    [
        {
            "time": "2018-01-03",
            "original_text": "FDA Turns Down IMMU's Breast Cancer Drug, MGNX/LLY Deal Progresses, ZFGN Abuzz",
            "features": {
                "keywords": [
                    "FDA",
                    "Turns Down",
                    "Breast Cancer Drug",
                    "MGNX/LLY Deal",
                    "ZFGN"
                ],
                "sentiment_score": -0.6,
                "policy_related": "true",
                "investment_strategy": "false",
                "sector_focus": [
                    "healthcare",
                    "pharmaceuticals"
                ],
                "causal_factor": "true",
                "causal_impact": "negative",
                "affected_by_time_series": "false",
                "ts_effect_direction": "none"
            },
            "scores": {
                "News_content": "FDA Turns Down IMMU's Breast Cancer Drug, MGNX/LLY Deal Progresses, ZFGN Abuzz",
                "Correlation": 9,
                "Sentiment": 3,
                "Importance": 8,
                "Impact": 7,
                "Duration": 6,
                "Entity_Density": 8,
                "Market_Scope": 5,
                "Time_Proximity": 7,
                "Headline_Structure": 9,
                "Source_Recency": 8
            }
        },
        {
            "time": "2018-01-04",
            "original_text": "Lilly's 10-Day Sprint For Loxo Could Put Other Names On The Table",
            "features": {
                "keywords": [
                    "Lilly",
                    "Loxo",
                    "Acquisition",
                    "Deal"
                ],
                "sentiment_score": 0.7,
                "policy_related": "false",
                "investment_strategy": "true",
                "sector_focus": [
                    "healthcare",
                    "biotech"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "true",
                "ts_effect_direction": "positive"
            },
            "scores": {
                "News_content": "Lilly's 10-Day Sprint For Loxo Could Put Other Names On The Table",
                "Correlation": 8,
                "Sentiment": 7,
                "Importance": 7,
                "Impact": 6,
                "Duration": 5,
                "Entity_Density": 6,
                "Market_Scope": 8,
                "Time_Proximity": 7,
                "Headline_Structure": 8,
                "Source_Recency": 7
            }
        },
        {
            "time": "2018-01-05",
            "original_text": "Ligand (LGND) Takes a Hit on Citron's Negative Research Report",
            "features": {
                "keywords": [
                    "Ligand",
                    "Citron",
                    "Negative Research",
                    "Hit"
                ],
                "sentiment_score": -0.8,
                "policy_related": "false",
                "investment_strategy": "true",
                "sector_focus": [
                    "biotech"
                ],
                "causal_factor": "true",
                "causal_impact": "negative",
                "affected_by_time_series": "true",
                "ts_effect_direction": "negative"
            },
            "scores": {
                "News_content": "Ligand (LGND) Takes a Hit on Citron's Negative Research Report",
                "Correlation": 9,
                "Sentiment": 2,
                "Importance": 8,
                "Impact": 7,
                "Duration": 4,
                "Entity_Density": 9,
                "Market_Scope": 4,
                "Time_Proximity": 8,
                "Headline_Structure": 8,
                "Source_Recency": 8
            }
        },
        {
            "time": "2018-01-06",
            "original_text": "Citron Says Ligand Has 80% Downside in Explosive Note",
            "features": {
                "keywords": [
                    "Citron",
                    "Ligand",
                    "80% Downside",
                    "Explosive Note"
                ],
                "sentiment_score": -0.9,
                "policy_related": "false",
                "investment_strategy": "true",
                "sector_focus": [
                    "biotech"
                ],
                "causal_factor": "true",
                "causal_impact": "negative",
                "affected_by_time_series": "true",
                "ts_effect_direction": "negative"
            },
            "scores": {
                "News_content": "Citron Says Ligand Has 80% Downside in Explosive Note",
                "Correlation": 9,
                "Sentiment": 1,
                "Importance": 9,
                "Impact": 8,
                "Duration": 5,
                "Entity_Density": 9,
                "Market_Scope": 3,
                "Time_Proximity": 9,
                "Headline_Structure": 10,
                "Source_Recency": 9
            }
        },
        {
            "time": "2018-01-07",
            "original_text": "Dealmaking surge confirms the stock market got far too ch...",
            "features": {
                "keywords": [
                    "Dealmaking",
                    "surge",
                    "stock market"
                ],
                "sentiment_score": 0.6,
                "policy_related": "false",
                "investment_strategy": "true",
                "sector_focus": [
                    "general market"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "true",
                "ts_effect_direction": "positive"
            },
            "scores": {
                "News_content": "Dealmaking surge confirms the stock market got far too ch...",
                "Correlation": 5,
                "Sentiment": 6,
                "Importance": 6,
                "Impact": 5,
                "Duration": 5,
                "Entity_Density": 3,
                "Market_Scope": 9,
                "Time_Proximity": 6,
                "Headline_Structure": 7,
                "Source_Recency": 6
            }
        },
        {
            "time": "2018-01-08",
            "original_text": "Jim Cramer: There's a Ton More Deals in the Pipe",
            "features": {
                "keywords": [
                    "Jim Cramer",
                    "More Deals",
                    "Pipeline"
                ],
                "sentiment_score": 0.8,
                "policy_related": "false",
                "investment_strategy": "true",
                "sector_focus": [
                    "general market"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "true",
                "ts_effect_direction": "positive"
            },
            "scores": {
                "News_content": "Jim Cramer: There's a Ton More Deals in the Pipe",
                "Correlation": 6,
                "Sentiment": 7,
                "Importance": 7,
                "Impact": 6,
                "Duration": 5,
                "Entity_Density": 4,
                "Market_Scope": 8,
                "Time_Proximity": 7,
                "Headline_Structure": 8,
                "Source_Recency": 7
            }
        }
    ]
]